The Beauty Tech Group Upgrades Full Year Expectations After Strong H1 Performance

The Beauty Tech Group FY26 upgrade is clearly positive for investors

This is the kind of trading update shareholders usually want to see. The Beauty Tech Group says trading in the first half of 2026 has been strong enough for the board to lift full-year expectations, with both revenue and adjusted EBITDA now expected to come in ahead of prior market forecasts.

In plain English, the business is selling more and making better margins while doing it. That combination matters because strong sales on their own are nice, but strong sales with improving profitability are far more powerful.

Metric	Previous market expectation	New board expectation	Implied uplift
FY26 revenue	£161.7 million	No less than £170 million	At least £8.3 million, or 5.1%
FY26 adjusted EBITDA	£41.5 million	No less than £45 million	At least £3.5 million, or 8.4%

What The Beauty Tech Group said in its H1 FY26 trading update

The company has not released full interim numbers yet, but it has given the market a clear steer. Revenue for the six months to 30 June 2026 is expected to be materially ahead of the prior year period, with growth across its core business, all key markets and all key channels.

That is an important detail. It suggests this is not just one product or one geography doing the heavy lifting. The wording points to broad-based momentum across the business.

• H1 FY26 revenue is expected to be materially ahead of the prior year period
• Growth was seen across the core business, key markets and channels
• Margin improvement was also achieved
• FY26 revenue is now expected to be no less than £170 million
• FY26 adjusted EBITDA is now expected to be no less than £45 million
• Interim results are due in September 2026

Why the revenue and adjusted EBITDA upgrade matters so much

The headline here is not just that forecasts have gone up. It is that profit expectations appear to be rising faster than revenue expectations. That usually tells you the business model is starting to work harder, with operational leverage coming through.

Adjusted EBITDA means earnings before interest, tax, depreciation and amortisation, adjusted for certain items the company believes are not part of normal trading. It is not the same as cash profit, but it is still a widely watched measure because it gives a feel for the underlying earning power of the business.

The Beauty Tech Group margin improvement is the best part of this update

If I had to pick the most encouraging line in the RNS, it would be the one about margin improvement. Plenty of consumer-facing businesses can grow sales by spending aggressively on marketing or discounting, but that can leave profits under pressure.

Here, the company says strong revenue growth has been combined with a well-invested operating model to drive better margins. That implies the business is scaling sensibly rather than just chasing top-line growth at any cost.

Broad-based growth reduces the risk of a one-off bounce

The other standout point is the breadth of growth. Management says performance was strong across the core business and across all key markets and channels. For retail investors, that matters because it lowers the fear that one lucky product launch or one region has distorted the numbers.

It also fits the group’s structure. The Beauty Tech Group sells at-home beauty devices through direct-to-consumer e-commerce channels and selected international retailers, with brands including CurrentBody Skin, ZIIP Beauty and Tria Laser.

What is still missing from this Beauty Tech Group RNS

This is a positive update, but it is still only a trading update. There are a few things investors do not yet know, and they are worth keeping in mind.

• Exact H1 FY26 revenue is not disclosed
• Exact H1 FY26 adjusted EBITDA is not disclosed
• The level of margin improvement is not disclosed
• No regional or channel-by-channel breakdown is provided
• No detail is given on cash generation, inventory or net debt

That means the market has enough information to get excited, but not enough to fully test the quality of earnings yet. September’s interim results should give a much clearer picture.

Why product launches and clinical studies could support H2 FY26 growth

Management flagged two drivers for the second half. First, there are a number of product launches in the pipeline. Second, the company says the at-home beauty device market continues to grow at pace.

The chief executive also pointed to continued investment in research and clinical studies. That is more important than it might sound. In beauty technology, especially products using LED light, radio frequency, microcurrent and laser therapies, credibility matters. Clinical backing can help justify premium pricing and support repeat demand.

The October 2025 listing makes this upgrade more notable

The group only listed on the London Stock Exchange in October 2025. So, an upgrade less than a year after joining the market is a good look. Newly listed companies are often watched closely for any sign that IPO promises were too optimistic.

In this case, the company has done the opposite. It has upgraded expectations, which tends to build management credibility, provided the full numbers in September back up the message.

The risks investors should not ignore after this H1 update

Even strong updates come with caveats. This announcement includes the usual forward-looking statement warnings, and rightly so. Consumer demand can change, product launches can disappoint, and premium discretionary spending is rarely risk-free.

There is also the valuation angle, which the RNS does not cover. A good company can still be a poor investment if too much optimism is already baked into the share price. That is not disclosed here, so investors need to judge it separately.

My take on The Beauty Tech Group after this FY26 guidance upgrade

Overall, this reads as a genuinely strong statement. The board is not just saying trading is good – it is putting numbers behind that confidence by lifting full-year expectations to no less than £170 million of revenue and no less than £45 million of adjusted EBITDA.

The fact that profit expectations are being lifted alongside revenue is what makes this more convincing. That suggests demand is healthy and the operating model is doing its job.

The only real frustration is the lack of hard H1 detail. Investors do not yet have the exact first-half figures, and they do not have a full breakdown by geography, channel or brand. So while this update is clearly positive, it is not the final word.

My view is straightforward: this is the sort of RNS that strengthens the bull case. It shows momentum, improving profitability and management confidence heading into the second half. Now the company needs to deliver the full evidence in September.